How to Choose a Peptide Clinic in Australia: A Patient's Checklist

The number of providers offering peptide therapy in Australia has grown considerably in recent years. Alongside legitimate, medically supervised services operating under Australian regulatory requirements, there has been a corresponding rise in non-compliant providers — online sellers, grey-market suppliers, and services that offer prescriptions without genuine clinical assessment. For someone seeking responsible access to GP-prescribed peptide therapy, knowing how to identify a compliant, legitimate clinic has become an important patient skill.

This article sets out a practical checklist for evaluating any peptide clinic or telehealth provider in Australia. It covers the regulatory and clinical standards that a legitimate provider should meet, the questions worth asking before committing to care, and the warning signs that indicate a provider is not operating within the appropriate framework.

Why Choosing the Right Provider Matters Now

Peptide therapy in Australia occupies a specific regulatory space. Peptides prescribed for human use are Schedule 4 (Prescription Only) substances under the Poisons Standard. This means they require a valid prescription from an AHPRA-registered practitioner, must be compounded or dispensed by a licensed Australian compounding pharmacy, and cannot be legally sold without a prescription — whether in-person or online.

The current regulatory environment reflects increased scrutiny on the online peptide supply chain. The Therapeutic Goods Administration (TGA) has, over recent years, moved to clarify and enforce the boundaries of legitimate supply, particularly in response to the proliferation of overseas direct-to-consumer peptide websites and domestic grey-market operations marketing products as "research chemicals" or "not for human consumption." As of mid-2026, providers operating outside the prescription framework face escalating compliance action.

This matters for patients because it affects both safety and legality. A peptide sourced without a prescription, from an unlicensed supplier, or without medical oversight carries risks that go beyond regulatory non-compliance: unknown purity, no sterility assurance, no quality control, and no clinical monitoring. The distinction between a regulated medical pathway and grey-market supply is not merely administrative — it is clinically meaningful.

For an overview of how the regulated pathway compares to grey-market supply, see our article on GP-prescribed peptides versus grey-market supply in Australia.

Check 1 — AHPRA-Registered Prescribing Clinician

The single most important feature of any legitimate peptide clinic is an AHPRA-registered medical practitioner in the prescribing role.

In Australia, the authority to prescribe Schedule 4 medicines rests with appropriately registered health practitioners — typically medical practitioners (doctors) registered with the Medical Board of Australia under AHPRA. A prescription issued by anyone who is not appropriately registered does not constitute a valid prescription under Australian law.

How to verify AHPRA registration

AHPRA maintains a publicly searchable register of all registered practitioners in Australia. It is available at ahpra.gov.au and allows you to search by practitioner name, profession, and registration status. A legitimate clinic will provide the prescribing practitioner's full name without hesitation, enabling you to verify their registration independently.

When searching the register, check:

• That the practitioner is currently registered (not expired, suspended, or cancelled)
• That their registration type is appropriate for prescribing (e.g., general registration as a medical practitioner)
• That no conditions or undertakings on their registration would affect their prescribing authority

A legitimate, reputable clinic will not only tolerate this verification step — it will expect it.

Why "a doctor reviews every prescription" is not sufficient

Some services describe a review process in which a doctor approves prescriptions generated from patient questionnaires. This is not the same as a genuine clinical consultation. Under Australian prescribing standards, a valid prescription requires a genuine patient–practitioner relationship, an assessment of the individual's clinical circumstances, and a decision that reflects that individual's specific needs and history. A form-based or questionnaire-only pathway does not meet this standard.

Check 2 — Genuine Clinical Assessment, Not a Guaranteed Script

A legitimate clinic will never guarantee a prescription before a consultation has taken place. If a provider promises that you will receive a prescription as a condition of signing up, engaging with the service, or purchasing a package — that is a significant red flag about the quality of the medical oversight being offered.

The purpose of a clinical consultation is for a qualified practitioner to assess whether a particular treatment is appropriate for the individual in front of them. That assessment requires:

• A thorough medical history, including current medications, existing health conditions, and relevant family history
• Relevant pathology or investigations where indicated — for example, baseline blood panels that allow the practitioner to make an informed clinical decision and to monitor changes over time
• A discussion of the current state of the evidence for the substance under consideration, including its limitations
• An honest conversation about potential risks and side effects, including those that are not fully characterised for newer peptides
• An understanding of the patient's goals and expectations, and whether those align with what the evidence supports

If a consultation feels perfunctory — a short call with no review of pathology, no questions about your medical history, no discussion of risks — that reflects a lower standard of clinical care. For substances with a still-developing evidence base, this matters.

Pathology and baseline testing

For many peptide prescriptions, responsible clinical practice involves some level of baseline testing before commencing, and follow-up testing during or after a course. This is not bureaucratic overhead — it is how a clinician establishes a baseline, monitors for adverse effects, and makes informed ongoing decisions. Ask any clinic whether baseline pathology is part of their assessment process and what monitoring they conduct after prescribing.

Check 3 — Licensed Australian Pharmacy Supply

All prescription peptides in Australia must be dispensed by a licensed Australian compounding pharmacy. For peptide compounds, which are not typically available as manufactured registered products, this means a licensed compounding pharmacy — a pharmacy operating under TGA oversight that prepares medicines to the specifications set out in a prescription.

This matters because:

• Licensed compounding pharmacies in Australia operate under TGA Good Manufacturing Practice (GMP) standards or equivalent, including sterility testing, quality assurance, and accurate dosing
• Overseas suppliers are not subject to Australian GMP requirements — their manufacturing conditions, product quality, and sterility cannot be verified by you as the patient
• "Research vials" and grey-market peptide products are not the output of licensed pharmaceutical manufacturing and carry genuine risks of contamination, incorrect concentration, and microbial contamination

When evaluating a clinic, ask directly: which pharmacy supplies the medication, and what is that pharmacy's licensing status? A provider operating within the regulatory framework will be able to answer this clearly.

If a provider is shipping medication from overseas, sourcing from an unlicensed supplier, or is unwilling to identify the pharmacy — those are serious red flags that should prompt you to seek care elsewhere.

For more detail on how the regulated supply chain works, see our article on how to get peptides prescribed in Australia.

Check 4 — Transparent Pricing

The cost of peptide therapy in Australia is not standardised, and it varies between providers. That said, any legitimate, well-run clinic should be able to disclose its pricing structure clearly before you commit to care.

Fees you should expect to have disclosed upfront include:

• Initial consultation fee — the cost of the first appointment with the prescribing practitioner
• Follow-up consultation fees — the ongoing cost of review appointments (these are typically required for any responsible monitoring plan)
• Pathology costs — if baseline or ongoing testing is part of the clinical protocol, you should know what it will cost and whether it is included in any package
• Medication costs — the cost of the compounded prescription itself, which will typically vary depending on the substance and dosing specifications
• Dispensing and shipping fees — charged by the compounding pharmacy for preparation and delivery of the medication

Medicare and PBS coverage

Most peptide therapy in Australia is privately billed and is generally not covered by Medicare or the Pharmaceutical Benefits Scheme (PBS). Some telehealth consultation fees may attract a Medicare rebate depending on the clinical context, but the prescription medicine itself is unlikely to be PBS-subsidised. Transparent clinics will clarify this upfront rather than allowing patients to assume public subsidy where none exists.

Be cautious of pricing that seems unusually low, particularly for the medication component. Significantly underpriced peptide compounds may indicate compromises in the manufacturing or quality assurance process.

Check 5 — Ongoing Monitoring and Aftercare

Legitimate medical care does not end at the prescription. For any medicine — particularly one prescribed in the context of a still-developing evidence base — ongoing monitoring is a fundamental component of responsible clinical practice.

What responsible monitoring and aftercare looks like:

• Scheduled follow-up consultations at clinically appropriate intervals, with the prescribing practitioner (or a practitioner with access to your clinical records)
• Review of response and any side effects — not just a repeat script, but a genuine assessment of how the individual is responding
• Pathology review where relevant — particularly for peptides where monitoring certain biomarkers is clinically important
• Clear guidance on what to do if side effects occur — including which symptoms warrant contacting the clinic and which require urgent medical attention
• A pathway to dose adjustment or discontinuation — responsible prescribing includes clear processes for modifying or stopping treatment if clinically indicated

A clinic that issues a prescription and then has no structured follow-up process is not meeting the standard of care appropriate for prescription medicine management. For emerging peptides with limited long-term safety data, the monitoring component is especially important.

Ask any prospective provider: what does follow-up look like after a prescription is issued? How often will I have a review with a practitioner? What is the process if I experience side effects?

For more information on what to expect from medically supervised peptide therapy, see our article on are peptides safe in Australia?

Red Flags to Walk Away From

The following are indicators that a peptide provider is not operating within the appropriate regulatory and clinical framework. In the presence of any of these, it is advisable to seek care elsewhere.

"No prescription required." In Australia, peptides for human use are Schedule 4 medicines. Any service offering access to prescription peptides without a valid prescription is operating outside the law. This applies whether the product is described as a "supplement," a "research chemical," or a "wellness compound."

Guaranteed outcomes. No legitimate medical practitioner guarantees specific outcomes from a prescription medicine. Any provider that promises results — weight loss, muscle gain, improved energy, anti-ageing effects, or any other specific outcome — is making claims that are not consistent with responsible medical practice or with Australian consumer law.

Before-and-after marketing. Before-and-after presentations, transformation imagery, and testimonial-based marketing of prescription medicines to the general public are inconsistent with Australian advertising standards for prescription medicines. A clinic that leads with this type of marketing is prioritising sales over clinical standards.

Consultation is optional or absent. If a provider allows you to obtain a prescription without speaking to a practitioner — via a questionnaire alone, or without any genuine assessment — that is not compliant prescribing. The clinical consultation is not optional.

Reluctance to discuss side effects or limitations. A responsible prescriber will discuss what is not known about a substance, as well as what is. If a practitioner or clinic representative is evasive or dismissive when you ask about side effects, contraindications, or the limitations of the evidence, that is a concern.

No aftercare pathway. If a clinic has no structured follow-up and no clear process for managing side effects or concerns post-prescription, the level of clinical oversight is inadequate.

Cannot identify the dispensing pharmacy. A legitimate clinic can tell you which licensed Australian pharmacy is compounding your medication. If this question is met with vagueness or redirection, that is a red flag about the supply chain.

Overseas shipping or unlicensed supply. Medication shipped from overseas has not been dispensed through the Australian-regulated pharmacy supply chain. Regardless of how it is described, this does not constitute compliant access to a Schedule 4 medicine.

A Simple Patient Checklist

Use the following checklist when evaluating any peptide clinic or telehealth provider in Australia.

If the answer to any of these questions gives you pause, raise it directly with the provider. A legitimate, well-run clinic will welcome the question.

Frequently Asked Questions

Do I need a GP referral to see a peptide telehealth clinic?

Generally, no. Most telehealth peptide clinics in Australia operate as primary care services, meaning you can book directly without a referral. However, the clinician you see is still required to be AHPRA-registered and to conduct a genuine clinical assessment. In some cases — particularly where a specific health condition is relevant to the prescribing decision — the clinic may recommend you also inform or involve your regular GP.

Is telehealth peptide care legitimate?

Yes — telehealth is a recognised and regulated mode of medical care in Australia. An AHPRA-registered practitioner conducting a telehealth consultation is subject to the same professional and legal obligations as they would be in an in-person setting. The prescribing standards, the pharmacy supply requirements, and the TGA classification of the medicines involved are identical. Telehealth is not a regulatory loophole — it is an alternative delivery model for the same regulated medical framework.

Does Medicare cover peptide therapy?

For most peptide therapy prescribed in a telehealth or private clinic context, Medicare does not cover the cost of the medication. Some telehealth consultation fees may attract a Medicare rebate depending on the clinical circumstances and the way the consultation is structured. The compounded prescription medicine itself is not PBS-subsidised. Patients should budget for the full private cost of both the consultation and the medication. Any legitimate clinic will disclose this upfront.

What is the difference between a compounding pharmacy and a regular pharmacy?

A compounding pharmacy prepares individualised medicines to the specifications set out in a prescription — combining active pharmaceutical ingredients to create a product that is not available as a standard manufactured medicine. In Australia, compounding pharmacies that compound medicines for human use must operate under TGA oversight and meet relevant quality and safety standards. Not all compounding pharmacies are equivalent in their standards; a legitimate peptide clinic will work with pharmacies whose licensing and quality standards they can verify and communicate to patients.

What should I do if I've already purchased peptides from an unregulated source?

If you have obtained prescription peptides without a valid Australian prescription — whether from an overseas supplier, a grey-market domestic source, or a "research chemical" vendor — the appropriate next step is to discuss your situation with an AHPRA-registered medical practitioner. A doctor can assess your clinical circumstances, advise on any risks, and help you understand the appropriate pathway going forward. This is not a situation that benefits from continuing outside the regulated framework.

Summary

Choosing a peptide clinic in Australia requires more than finding a provider that offers the substances you are interested in. The regulatory framework governing prescription peptides exists to protect patients — and understanding the standards a legitimate clinic must meet puts you in a position to identify compliant care and avoid the real risks associated with grey-market or non-compliant providers.

The five checks outlined in this article — AHPRA-registered prescribing clinician, genuine clinical assessment, licensed Australian pharmacy supply, transparent pricing, and structured monitoring — represent the baseline of responsible, compliant peptide care. When combined with the red flags to avoid, they provide a practical framework for evaluating any provider.

High Performance Human is a GP-prescribed telehealth clinic operating within the Australian regulatory framework. Our consultations are conducted by AHPRA-registered medical practitioners, medications are dispensed by licensed Australian compounding pharmacies, and our model is built on genuine clinical assessment and ongoing, medically supervised care — not guaranteed outcomes or form-based prescribing.